A selection of major announcements

1. Zijin Mining: The subsidiary spent about 690 million yuan to subscribe for a targeted additional 28.4813 million shares of Solaris common stock

$ZIJIN MINING (02899.HK)$According to the announcement, Jinlong, a wholly-owned subsidiary in Singapore, subscribed a total of 28.4812 million shares of Solaris (Solaris) at a price of 4.55 Canadian dollars per share, at a total cost of about 130 million Canadian dollars (about 690 million yuan). After completion, Golden Dragon will become the second-largest shareholder of Solaris, holding 15% of the shares.

Listed in Toronto, Solaris is a mining company focused on the exploration and development of mineral resources. The flagship asset is 100% interest in the Huarincha porphyry copper project in Ecuador.

2. Express sales: Net profit returned to mother for the first fiscal quarter was 107.8 billion yen, an increase of 26.7% over the previous year

$Fast Retailing (06288.HK)$Total consolidated income for the first quarter of fiscal year 2024 was 810.8 billion yen, up 13.2% from the same period last year; total consolidated operating profit was 146.6 billion yen, up 25.3% year on year. Among them, a net increase of 15.7 billion yen was recorded under financing income and costs. This was mainly due to net interest income of 12.7 billion yen and net exchange income of 3 billion yen after book values such as financial assets denominated in foreign currency were converted to yen. As a result, quarterly profit before income tax was 162.4 billion yen, up 28.1% year-on-year, and parent company owners should account for quarterly profit of 107.8 billion yen, an increase of 26.7%.

3. Shanghai Pharmaceutical: Telmisartan hydrochlorothiazide tablets passed generic drug consistency evaluation

$SH PHARMA (02607.HK)$According to the announcement, Changzhou Pharmaceutical Factory, a holding subsidiary, received the “Drug Supplement Application Approval Notice” for telmisartan hydrochlorothiazide tablets issued by the State Drug Administration. The drug passed the consistent evaluation of generic drug quality and efficacy. Telmisartan hydrochlorothiazide tablets are mainly used to treat essential hypertension. They were developed by Boehringer Ingelheim and first marketed in the US in 2000.

4. Baiguoyuan plans to use up to 634 million yuan to repurchase H shares

$PAGODA GP (02411.HK)$Announcement. The board of directors hereby announces that it intends to exercise its power under the authorization to repurchase H shares to repurchase the company's H shares. According to the authorization to repurchase H shares, the company was authorized to repurchase up to 10% of the total number of H shares issued at the time of the shareholders' meeting, or up to a total of 118.3 million H shares.

Financial performance

$Fast Retailing (06288.HK)$: Net profit to mother of 107.8 billion yen for the first fiscal quarter increased 26.7% year over year

$VALUE PARTNERS (00806.HK)$Yingxi: Estimated consolidated profit attributable to company owners of HK$23 million for the year

Investment and operation

$GREENLAND HK (00337.HK)$: 2023 contract sales of 18.361 billion yuan

$BOC AVIATION (02588.HK)$: Aircraft utilization increased from 96% in 2022 to 99% in 2023

$SH PHARMA (02607.HK)$: Telmisartan hydrochlorothiazide tablets passed generic drug consistency evaluation

$CDB LEASING (01606.HK)$Spending 723 million yuan to purchase vehicles used in operating leasing business

Equity incentives

$ZHOU HEI YA (01458.HK)$: The trustee purchased 48.4 million shares under the restricted share unit plan

Repurchase cancellation

$PAGODA GP (02411.HK)$It is planned to use up to 634 million yuan to repurchase H shares

$TENCENT (00700.HK)$1.74 million shares were repurchased at HK$500 million on January 11

$MEITUAN-W (03690.HK)$5.31 million shares were repurchased at HK$400 million on January 11

$AIA (01299.HK)$2.13 million shares were repurchased at HK$135 million on January 11

$HSBC HOLDINGS (00005.HK)$: Repurchase approximately 5.722,700 shares on the London Stock Exchange and the Hong Kong Stock Exchange

$XIAOMI-W (01810.HK)$On January 11, it cost HK$50.59 million to buy back 3.5 million shares

$BEKE-W (02423.HK)$On January 10, it cost 5 million US dollars to buy back 1.01 million shares

$SWIRE PACIFIC A (00019.HK)$On January 11, it cost HK$21.82 million to buy back 340,000 shares

$PRU (02378.HK)$On January 10, it spent £3.03 million to buy back 360,000 shares

$YUM CHINA (09987.HK)$On January 10, $2.4 million was spent to buy back 62,600 shares

$COSCO SHIP HOLD (01919.HK)$On January 11, it cost HK$176.652 million to repurchase 2.31 million shares

$HAIER SMARTHOME (06690.HK)$On January 11, it spent 12.925 million yuan to buy back 600,000 A-shares

$ESR (01821.HK)$On January 11, it cost HK$127.43 million to buy back 1.156,800 shares

$TIMES ELECTRIC (03898.HK)$On January 11, it cost HK$11.889 million to buy back 574,600 shares

$WANT WANT CHINA (00151.HK)$On January 11, it cost HK$9.255 million to repurchase 2 million shares

$SF INTRA-CITY (09699.HK)$809,000 shares were repurchased at HK$8.37 million on January 11

edit/new